Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R Mutations

计划入组 8 人 · 首次发布于 2017 年 2 月 2 日

A Registry to Capture Patient Outcomes With KRAS G12R Altered Advanced Pancreatic Ductal Adenocarcinoma Treated With MEK Inhibitor-based Combination Therapy

计划入组 80 人 · 首次发布于 2022 年 11 月 30 日

A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors

计划入组 158 人 · 首次发布于 2023 年 2 月 14 日

KRAS-G12R(Revolution Medicines)

KRAS G12R inhibitors(The University of California, San Francisco)

KRAS-G12V

Cardiff Oncology

United States

KRAS Mutation Subtypes Linked to Varying Outcomes in Pancreatic Cancer

Elicio's ELI-002 Cancer Vaccine Shows Promising Results in Phase 1 Trial for Pancreatic and Colorectal Cancer

Pasithea's PAS-004 Shows Strong Target Engagement with 91% pERK Inhibition in Phase 1 Cancer Trial